natgillin/translations-raw huggingface dataset:
Antiviral aktivitet in vitro: Den koncentration af emtricitabin, som er nødvendig for 50% hæmning (IC50) af laboratoriemæssige og kliniske isolater af hiv 1, lå inden for området 0,0013-0,5 µmol/l. 
Antiviral activity in vitro: The 50% inhibitory concentration (IC50) value for emtricitabine against laboratory and clinical isolates of HIV-1 was in the range of 0.0013 to 0.5 µmol/l.
De bedes venligst læse indlægssedlerne til de andre slags antiretroviral medicin som vejledning i at indtage medicinen korrekt. 
Please refer to the package leaflets of the other antiretrovirals for guidance on how to take those medicines.
Samtidig administration af emtricitabin og lægemidler, som elimineres ved aktiv tubulær sekretion, kan føre til en stigning i serumkoncentrationer af enten emtricitabin eller et samtidig administreret lægemiddel på grund af konkurrencen om denne eliminationsvej. 
Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product due to competition for this elimination pathway.
• Aktivt stof: emtricitabin. 
• The active substance is emtricitabine.
Generelt lignede emtricitabins farmakokinetik hos HBV-inficerede forsøgspersoner den hos raske forsøgspersoner og hos hiv-inficerede forsøgspersoner. 
In general, emtricitabine pharmacokinetics in HBV infected subjects were similar to those in healthy subjects and in HIV infected subjects.
• hovedpine, diarré, kvalme 
• headache, diarrhoea, feeling sick (nausea)
Det gennemsnitlige AUC hos 77 børn og unge, som fik 6 mg/kg emtricitabin en gang daglig som oral opløsning eller 200 mg emtricitabin som hårde kapsler en gang daglig, kunne sammenlignes med det gennemsnitlige AUC på 10,0 µg·t/ml hos 20 voksne, som fik 200 mg hårde kapsler en gang daglig. 
The mean AUC in 77 infants, children and adolescents receiving 6 mg/kg emtricitabine once daily as oral solution or 200 mg emtricitabine as hard capsules once daily was similar to the mean AUC of 10.0 µg·h/mL in 20 adults receiving 200 mg hard capsules once daily.
Hvis De ved et uheld tager for meget Emtriva som oral opløsning, skal De kontakte lægen eller den nærmeste skadestue for at få råd. 
If you accidentally take too much Emtriva oral solution, contact your doctor or nearest emergency department for advice.
Patienter med nedsat nyrefunktion: Emtricitabin elimineres ved renal udskillelse, og eksponeringen for emtricitabin steg signifikant hos patienter med nyreinsufficiens. 
Patients with renal impairment: Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency.
• Øvrige indholdsstoffer: sukkervataroma, dinatriumedetat, saltsyre, methylparahydroxybenzoat (E218), propylenglycol, propylparahydroxybenzoat (E216), natriumhydroxid, monobasisk natriumphosphathydrat, sunset yellow FCF (E110), renset vand, xylitol (E967). 
• The other ingredients are: cotton candy flavouring, disodium edetate, hydrochloric acid, methyl parahydroxybenzoate (E218), propylene glycol, propyl parahydroxybenzoate (E216), sodium hydroxide, sodium phosphate monobasic hydrate, sunset yellow (E110), purified water, xylitol (E967).
Anbefalet dosis af Emtriva 10 mg/ml oral opløsning hver 24. time 
Recommended dose of Emtriva 10 mg/mL oral solution every 24 hours
Den systemiske emtricitabineksponering (gennemsnit ± standardafvigelsen) steg fra 11,8 ±2,9 µg·t/ml hos forsøgspersoner med normal nyrefunktion til 19,9 ±1,1, 25,0 ± 5,7 og 34,0 ± 2,1 µg·t/ml hos patienter med henholdsvis mildt, moderat og svært nedsat nyrefunktion. 
The systemic emtricitabine exposure (mean ± standard deviation) increased from 11.8 ± 2.9 µg·h/mL in subjects with normal renal function to 19.9 ± 1.1, 25.0 ± 5.7 and 34.0 ± 2.1 µg·h/mL, in patients with mild, moderate and severe renal impairment, respectively.
Der skal udvises forsigtighed, når emtricitabin gives samtidig med lægemidler, som elimineres ved aktiv tubulær sekretion, da sådan samtidig administration kan føre til en stigning i serumkoncentrationer af enten emtricitabin eller et samtidig administreret lægemiddel på grund af konkurrencen om denne eliminationsvej (se pkt. 
Caution should be exercised when emtricitabine is co-administered with medicinal products that are eliminated by active tubular secretion as such co-administration may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product, due to competition for this elimination pathway (see section 4.5).
Bægeret har streger, der angiver hver 1 ml opløsning. 
The cup has lines to indicate each mL of solution.
Da det er mere sandsynligt, at ældre patienter har nedsat nyrefunktion, skal der udvises forsigtighed ved behandling af ældre patienter med Emtriva. 
Elderly patients are more likely to have decreased renal function; therefore caution should be exercised when treating elderly patients with Emtriva.
Kapslen indeholder: mikrokrystallinsk cellulose (E460), crospovidon, magnesiumstearat (E572), povidon (E1201) 
Capsule contents: microcrystalline cellulose (E460), crospovidone, magnesium stearate (E572), povidone (E1201)
Hjælpestof(fer), som behandleren skal være opmærksom på Hver dosis (24 ml) indeholder 36 mg methylparahydroxybenzoat (E218), 3,6 mg propylparahydroxybenzoat (E216), 1,2 mg sunset yellow FCF (E110), 480 mg propylenglycol og har et natriumindhold på 36 mg. 
Each dose (24 mL) contains 36 mg methyl parahydroxybenzoate (E218), 3.6 mg propyl parahydroxybenzoate (E216), 1.2 mg sunset yellow (E110), 480 mg propylene glycol and has a sodium content of 36 mg.
Hos patienter med kronisk hepatitis B eller C, som behandles med CART, er der en øget risiko for svære og potentielt letale, hepatiske uønskede hændelser. 
Patients with chronic hepatitis B or C infection treated with CART are at increased risk of experiencing severe, and potentially fatal, hepatic adverse events.
Hvis patienten kaster op inden for 1 time efter at have taget Emtriva, skal der tages en ny dosis. 
If the patient vomits within 1 hour of taking Emtriva, another dose should be taken.
allergiske reaktioner Metabolisme og ernæring: Almindelig: 
Metabolism and nutrition disorders: Common:
Dosering Emtriva 200 mg hårde kapsler kan tages med eller uden mad. 
Emtriva 200 mg hard capsules may be taken with or without food.
Derfor bør det kliniske respons på behandlingen og nyrefunktionen monitoreres tæt hos disse patienter (se pkt. 
Therefore, clinical response to treatment and renal function should be closely monitored in these patients (see section 4.4).
Indlægsseddel: Information til brugeren Emtriva 10 mg/ml oral opløsning 
Package leaflet: Information for the user Emtriva 10 mg/mL oral solution
forhøjet amylase, herunder forhøjet pancreasamylase, forhøjet serum-lipase, opkastning, abdominalsmerter, dyspepsi 
elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia Hepatobiliary disorders: Common:
De virker ved at gribe ind i den normale måde, som et enzym (reverse transkriptase) arbejder på, og som er nødvendigt for at virus kan reproducere sig selv. 
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) which works by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the HIV virus to reproduce itself.
Hvis Emtriva seponeres hos patienter, der samtidig er inficeret med hiv og hepatitis B-virus (HBV), skal disse patienter monitoreres tæt for tegn på eksacerbation af hepatitis (se pkt. 
If Emtriva is discontinued in patients co-infected with HIV and hepatitis B virus (HBV), these patients should be closely monitored for evidence of exacerbation of hepatitis (see section 4.4).
Derfor kan børn, som vejer mindst 33 kg, enten tage én 200 mg hård kapsel daglig eller den orale opløsning op til en maksimal dosis af 240 mg (24 ml), en gang daglig. 
Therefore, children who weigh at least 33 kg may take either one 200 mg hard capsule daily or the oral solution up to a maximum dose of 240 mg (24 mL), once daily.
Pædiatrisk population: Den anbefalede dosis af Emtriva 10 mg/ml oral opløsning er 6 mg/kg op til maksimalt 240 mg (24 ml) en gang dagligt. 
Paediatric population: The recommended dose of Emtriva 10 mg/mL oral solution is 6 mg/kg up to a maximum of 240 mg (24 mL) once daily.
Tabel 1: Retningslinjer for dosisinterval for 200 mg hårde kapsler, justeret i forhold til kreatininclearance 
Table 1: Dose interval guidelines for 200 mg hard capsules adjusted according to creatinine clearance
Emtriva 10 mg/ml oral opløsning kan tages med eller uden mad. 
Emtriva 10 mg/mL oral solution may be taken with or without food.
Trykfarven indeholder Sort jernoxid (E172) Shellac (E904) 
Printing ink containing Black iron oxide (E172) Shellac (E904)
Immunsystemet: Almindelig: 
Immune system disorders: Common:
Der foreligger utilstrækkelige data for virkningen af emtricitabin på det ammede barn. 
There is insufficient information on the effects of emtricitabine in newborns/infants.
Emtriva 10 mg/ml oral opløsning skal tages en gang dagligt oralt, med eller uden mad. 
Emtriva 10 mg/mL oral solution should be taken once daily, orally with or without food.
De behøver ikke tage en ny dosis, hvis De kaster op mere end en time efter, De har taget Emtriva. 
You do not need to take another dose if you were sick more than an hour after taking Emtriva.
Børn på 4 måneder og derover, som vejer mindst 33 kg, kan enten tage én 200 mg hård kapsel dagligt, eller kan tage emtricitabin som oral opløsning op til maksimalt 240 mg en gang dagligt. 
Children aged 4 months and over, who weigh at least 33 kg may either take one 200 mg hard capsule daily or may take emtricitabine as the oral solution up to a maximum of 240 mg once daily.
Pakningsstørrelse: 30 hårde kapsler. 
Pack size: 30 hard capsules.
Ud over de bivirkninger, som voksne oplevede, forekom anæmi og misfarvning af huden hyppigere i kliniske studier med hiv-inficerede pædiatriske patienter (se pkt. 
In addition to the adverse reactions experienced by adults, anaemia and skin discolouration occurred more frequently in clinical trials involving HIV infected paediatric patients (see section 4.8).
Administration Emtriva 200 mg hårde kapsler skal tages en gang dagligt, oralt, med eller uden mad. 
Method of administration Emtriva 200 mg hard capsules should be taken once daily, orally with or without food.
Hos patienter med fremskreden leversygdom eller levercirrose bør behandlingen ikke ophøre, da det hos nogle patienter kan medføre forværring af hepatitis. 
In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of hepatitis.
Voksne: Den anbefalede dosis af Emtriva 10 mg/ml oral opløsning er 240 mg (24 ml) en gang daglig. 
Adults: The recommended dose of Emtriva 10 mg/mL oral solution is 240 mg (24 mL) once daily.
Tabel 1 nedenfor giver retningslinjer for justering af dosisintervallet for 200 mg hårde kapsler i henhold til graden af nyreinsufficiens. 
Table 1 below provides dose interval adjustment guidelines for the 200 mg hard capsules according to the degree of renal insufficiency.
• Tag altid den dosis, Deres læge har anbefalet for at sikre, at medicinen er fuldt ud effektiv og for at reducere udviklingen af resistens mod behandlingen. 
This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment.
Én 200 mg hård kapsel hver 96. time 
One 200 mg hard capsule every 96 hours
Virus, som var resistente over for zidovudin, didanosin og NNRTIs, beholdt deres følsomhed over for emtricitabin (IC50 = 0,002 µmol/l-0,08 µmol/l). 
Viruses resistant to zidovudine, didanosine and NNRTIs retained their sensitivity to emtricitabine (IC50= 0.002 µmol/l to 0.08 µmol/l).
Virus, som var resistente over for zidovudin, didanosin og NNRTIs, beholdt deres følsomhed over for emtricitabin (IC50= 0,002 µmol/l-0,08 µmol/l). 
Viruses resistant to zidovudine, didanosine and NNRTIs retained their sensitivity to emtricitabine (IC50 = 0.002 µmol/l to 0.08 µmol/l).
Propylparahydroxybenzoat (E216) Natriumhydroxid 
Propyl parahydroxybenzoate (E216) Sodium hydroxide
Kapslens skal: gelatine, indigotin (E132), titandioxid (E171) Trykfarven indeholder: sort jernoxid (E172), shellac (E904) 
Capsule shell: gelatin, indigotine (E132), titanium dioxide (E171) Printing ink containing: black iron oxide (E172), shellac (E904)
In vitro hæmmede emtricitabin ikke metabolisme medieret af en af de følgende humane CYP450isoformer: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 og 3A4. 
In vitro, emtricitabine did not inhibit metabolism mediated by any of the following human CYP450 isoforms: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4.
vesikulobulløst udslæt, pustuløst udslæt, makulopapuløst udslæt, udslæt, pruritus, urticaria, misfarvning af huden (forøget pigmentering)1,2 
vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)1,2
Almene symptomer og reaktioner på administrationssstedet: Almindelig: 
General disorders and administration site conditions: Common:
Hvilken mængde 10 mg/ml oral opløsning skal tages (ml) 
How much 10 mg/mL solution to take (mL)
Hvis De - inden for 12 timer efter, dosis normalt tages - kommer i tanker om, at De har glemt at tage en dosis, skal De tage den så hurtigt som muligt og derefter tage den næste dosis på det normale tidspunkt. 
If you do miss a dose of Emtriva within 12 hours of when it is usually taken, take it as soon as you can, and then take your next dose at its regular time.
Tabel 1 nedenfor giver daglige doser af Emtriva 10 mg/ml oral opløsning i henhold til graden af nyreinsufficiens. 
Table 1 below provides daily doses of Emtriva 10 mg/mL oral solution according to the degree of renal insufficiency.
Følgende bivirkninger er ikke almindelige (de kan opstå hos op til 1 ud af 100 patienter): 
The following side effects are uncommon (these can affect up to 1 in every 100 patients):
Emtricitabin hæmmede ikke in vitro lægemiddelmetabolisme medieret af følgende humane CYP450-isoenzymer: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 og 3A4. 
Emtricitabine did not inhibit in vitro drug metabolism mediated by the following human CYP450 isoenzymes: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4.
Før De påbegynder behandlingen, kan Deres læge tage blodprøver for at bedømme nyrefunktionen og råder Dem måske til at tage en reduceret dosis af den orale opløsning eller ordinerer Emtriva hårde kapsler til Dem. Deres læge kan også tage blodprøver under behandlingen for at overvåge Deres nyrer. 
Before starting treatment, your doctor may order blood tests to assess kidney function and may advise you to take a reduced dose of the oral solution or prescribe Emtriva hard capsules.
De behøver ikke tage en ny kapsel, hvis De kaster op mere end en time efter, De har taget Emtriva. 
You do not need to take another capsule if you were sick more than an hour after taking Emtriva.
Hver ml af Emtriva oral opløsning indeholder 10 mg emtricitabin (10 mg/ml). 
One mL of Emtriva oral solution contains 10 mg of emtricitabine (10 mg/mL).
Virkning og anvendelse Emtriva anvendes til behandling af human immundefekt virus (hiv) hos voksne og børn på 
What Emtriva is and what it is used for Emtriva is a treatment for Human Immunodeficiency Virus (HIV) infection in adults, children and infants aged 4 months and over.
Hvis patienten kaster op mere end 1 time efter at have taget Emtriva, skal patienten ikke tage en ny dosis. 
If the patient vomits more than 1 hour after taking Emtriva they do not need to take another dose.
Tabel 1: Daglige doser af Emtriva 10 mg/ml oral opløsning, justeret i forhold til kreatininclearance 
Table 1: Daily doses of Emtriva 10 mg/mL oral solution adjusted according to creatinine clearance
• udslæt (herunder røde pletter og skjolder undertiden med blærer eller hævelse af huden), som kan være allergiske reaktioner, kløe, ændringer i hudfarven, herunder pletvis mørkfarvning af huden 
• rashes (including red spots or blotches sometimes with blistering and swelling of the skin),
Ved afprøvning for aktivitet mod laboratoriestammer af HBV lå emtricitabins IC50-værdi inden for området 0,01-0,04 µmol/l. 
When tested for activity against laboratory strains of HBV, the IC50value for emtricitabine was in the range of 0.01 to 0.04 µmol/l.
Hver ml indeholder 10 mg emtricitabin. 
Each mL contains 10 mg of emtricitabine.
Følgende bivirkninger er almindelige (de kan opstå hos op til 10 ud af 100 patienter): 
The following side effects are common (these can affect up to 10 in every 100 patients):
Emtricitabin er aktiv in vitro mod HBV. Der foreligger imidlertid begrænsede data om virkningen og sikkerheden af emtricitabin (som en 200 mg hård kapsel én gang daglig) hos patienter, som samtidig er inficerede med hiv og HBV. 
However, limited data are available on the efficacy and safety of emtricitabine (as a 200 mg hard capsule once daily) in patients who are co-infected with HIV and HBV.
Behandlingen bør ikke seponeres hos patienter med fremskreden leversygdom eller levercirrose, da hepatitis-eksacerbationer efter behandlingen kan føre til hepatisk dekompensation. 
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbations of hepatitis may lead to hepatic decompensation.
Ældre: Emtriva er ikke blevet undersøgt hos patienter over 65 år. 
Elderly: Emtriva has not been studied in patients over the age of 65.
Methylparahydroxybenzoat (E218) og propylparahydroxybenzoat (E216) kan give allergiske reaktioner (kan optræde efter behandlingen). 
The methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) may cause allergic reactions (possibly delayed).
Anbefalet dosisinterval for 200 mg hårde kapsler 
Recommended dose interval for 200 mg hard capsules
4.8, Resumé af bivirkninger i tabelform) forekom følgende bivirkninger hyppigere hos pædiatriske patienter: anæmi var almindelig (9,5%), og misfarvning af huden (forøget pigmentering) var meget almindelig (31,8%) hos pædiatriske patienter. 
In addition to the adverse reactions reported in adults (see section 4.8, Tabulated summary of adverse reactions), the following adverse reactions were observed more frequently in paediatric patients: anaemia was common (9.5%) and skin discolouration (increased pigmentation) was very common (31.8%) in paediatric patients.
Før De påbegynder behandlingen, kan Deres læge tage blodprøver for at bedømme nyrefunktionen og råder Dem måske til at tage kapslerne mindre hyppigt eller ordinerer Emtriva oral opløsning til Dem. Deres læge kan også tage blodprøver under behandlingen for at overvåge Deres nyrer. 
Before starting treatment, your doctor may order blood tests to assess kidney function and may advise you to take the capsules less often or prescribe Emtriva oral solution.
Nyreinsufficiens: Emtricitabin elimineres ved renal udskillelse og eksponering for emtricitabin steg signifikant hos patienter med nyreinsufficiens (se pkt. 
Renal insufficiency: Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency (see section 5.2).
Der findes en særskilt indlægsseddel til Emtriva 200 mg hårde kapsler. 
There is a separate Package Leaflet for Emtriva 200 mg hard capsules.
Emtriva 10 mg/ml oral opløsning Emtricitabin 
Emtriva 10 mg/mL oral solution Emtricitabine
Hos virologisk stabile, behandlingserfarne voksne viste det sig, at emtricitabin, i kombination med en NRTI (enten stavudin eller zidovudin) og en PI eller en NNRTI ikke var mindre effektiv end lamivudin med hensyn til procentdelen af responderende (< 400 kopier/ml) i 48 uger (77% emtricitabin, 82% lamivudin). 
In virologically stable treatment-experienced adults, emtricitabine, in combination with an NRTI (either stavudine or zidovudine) and a PI or an NNRTI was shown to be non-inferior to lamivudine with respect to the proportion of responders (< 400 copies/mL) through 48 weeks (77% emtricitabine, 82% lamivudine).
Derfor bør klinisk respons på behandling og nyrefunktionen monitoreres tæt hos patienter, som behandles med en reduceret dosis af emtricitabin (se pkt. 
Therefore, clinical response to treatment and renal function should be closely monitored in patients treated with a reduced dose of emtricitabine (see sections 4.2 and 5.2).
Én 200 mg hård kapsel hver 24. time 
One 200 mg hard capsule every 24 hours
Én 200 mg hård kapsel hver 72. time 
One 200 mg hard capsule every 72 hours
Hos virologisk stabile, behandlingserfarne voksne viste det sig, at emtricitabin, i kombination med en NRTI (enten stavudin eller zidovudin) og proteasehæmmer (PI) eller en NNRTI ikke var mindre effektiv end lamivudin med hensyn til procentdelen af responderende (< 400 kopier/ml) i 48 uger (77% emtricitabin, 82% lamivudin). 
In virologically stable treatment-experienced adults, emtricitabine, in combination with an NRTI (either stavudine or zidovudine) and a protease inhibitor (PI) or an NNRTI was shown to be non-inferior to lamivudine with respect to the proportion of responders (< 400 copies/mL) through 48 weeks (77% emtricitabine, 82% lamivudine).
Hepatitis-eksacerbationer efter seponering af behandling: Hos hiv-inficerede patienter, som samtidigt er inficerede med HBV, er der forekommet hepatitis-eksacerbationer efter seponering af behandlingen (se pkt. 
Exacerbations of hepatitis after discontinuation of treatment: In HIV infected patients co-infected with HBV, exacerbations of hepatitis may occur after discontinuation of treatment (see section 4.4).
Emtriva 200 mg hårde kapsler Emtricitabin 
Emtriva 200 mg hard capsules Emtricitabine
Emtriva er indiceret til behandling af voksne og børn på 4 måneder og derover inficerede med human immundefekt virus 1 (hiv 1) i kombination med andre antiretrovirale lægemidler. 
Emtriva is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infected adults and children aged 4 months and over.
Følgende bivirkninger er meget almindelige (de kan opstå hos flere end 10 ud af 100 patienter): 
The following side effects are very common (these can affect at least 10 in every 100 patients):
Der findes en særskilt indlægsseddel til Emtriva 10 mg/ml oral opløsning. 
There is a separate Package Leaflet for Emtriva 10 mg/mL oral solution.
Emtriva er ikke blevet undersøgt hos patienter over 65 år. 
Emtriva has not been studied in patients over 65 years of age.
Hvis De har taget for meget Emtriva 
If you take more Emtriva than you should
- Lægen har ordineret Emtriva til Dem personligt. 
- This medicine has been prescribed for you only.
På grund af denne forskel i biotilgængeligheden bør 240 mg emtricitabin administreret som den orale opløsning give samme plasmaniveauer som dem, der observeredes efter administration af én 200 mg emtricitabin hård kapsel. 
Due to this difference in bioavailability, 240 mg emtricitabine administered as the oral solution should provide similar plasma levels to those observed after administration of one 200 mg emtricitabine hard capsule.
Da det er mere sandsynligt, at ældre patienter har nedsat nyrefunktion, skal der udvises forsigtighed ved behandling af ældre patienter med Emtriva (se pkt. 
Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with Emtriva (see section 4.2).
Emtriva 10 mg/ml oral opløsning 
Emtriva 10 mg/mL oral solution
Methylparahydroxybenzoat (E218) Propylenglycol 
Methyl parahydroxybenzoate (E218) Propylene glycol
Emtriva 200 mg hårde kapsler 
Emtriva 200 mg hard capsules
Pakningsstørrelser og yderligere oplysninger Emtriva indeholder: 
Contents of the pack and other information What Emtriva contains
Kør ikke bil eller motorcykel og lad være med at cykle, og lad være med at arbejde med værktøj eller maskiner, hvis De bliver svimmel, når De tager Emtriva. 
If you experience dizziness while taking Emtriva, do not drive and do not use any tools or machines.
Hver hård kapsel Emtriva indeholder 200 mg emtricitabin. 
Each Emtriva hard capsule contains 200 mg of emtricitabine.